Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 4 25 20 SULFITE FREE W ELECT IN DEXTROSE 20 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 4 25 20 SULFITE FREE W ELECT IN DEXTROSE 20 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER.
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intravenous amino acids and dextrose provide essential nitrogen and calories for protein synthesis and energy metabolism. Electrolytes maintain osmotic balance and cellular function. Calcium is critical for neuromuscular transmission and bone health.
Travasol 4.25% in Dextrose 20% is a parenteral nutrition solution providing amino acids and carbohydrates. Amino acids serve as substrates for protein synthesis, while dextrose supplies calories to prevent catabolism and promote anabolism. The solution corrects nitrogen balance and provides energy.
Intravenous infusion: Adult dose is based on protein and caloric requirements. Typical dose: 1-2 L/day of this 4.25% amino acid, 20% dextrose solution, providing approximately 4.25 g amino acid/100 mL and 680 kcal/L. Infusion rate should be adjusted to avoid hyperglycemia, usually starting at 25-50 mL/hr and increasing gradually.
Intravenous administration via central line. Typical adult dose: 500-1000 mL/day of TRAVASOL 4.25% in dextrose 20% (providing 4.25 g amino acids and 20 g dextrose per 100 mL) as part of total parenteral nutrition. Infusion rate: not to exceed 0.8 g/kg/h of amino acids. Individualize based on metabolic needs.
None Documented
None Documented
Not applicable as a single entity; components have distinct half-lives: dextrose ~1.5-2 hours (glucose); amino acids ~5-10 minutes; electrolytes vary (e.g., calcium ~2-3 hours). Clinical context: continuous infusion achieves steady state.
Not applicable; components are endogenous nutrients. Dextrose half-life <15 min in normal renal function; amino acids have variable half-lives (minutes) due to rapid metabolism and incorporation. Clinical context: continuous infusion maintains steady state.
The amino acids and electrolytes are metabolized or utilized; dextrose is oxidized to CO2 and water. Renal excretion of nitrogen is ~60-80% as urea, with minor losses in feces (5-10%) and skin (2-5%). Electrolytes are excreted primarily renally.
Renal excretion; amino acids are reabsorbed or metabolized, excess nitrogen excreted as urea (renal). Dextrose is metabolized to CO2 and water. No significant biliary/fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution